Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction

M. V. Zhuravleva; S. V. Nedogoda; Yu. V. Gagarina; T. V. Marin

For citations:

Zhuravleva M.V., Nedogoda S.V., Gagarina Yu.V., Marin T.V. Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction. Russian Journal of Cardiology. 2024;29(7):6027. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6027. EDN: ZIARUH

Views PDF (Rus): 247

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Russian Journal of Cardiology

For citations:

Cookies policy